MelindaGPaulyMD

Pediatric Hematology & Oncology • Atlanta, GA

Pediatric Hematologic Oncology

Assistant Professor, Pediatrics, Emory University School of Medicine Medical Director of Oncology, Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta

Join to view full profile

Dr. Pauly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pauly's full profile

Already have an account?

Office
5461 Meridian Mark Rd
Ste 400
Atlanta, GA 30342
Phone+1 404-785-1112

Fax+1 404-785-3600

Education & Training

Emory University School of MedicineFellowship, Pediatric Hematology/Oncology, 2009 - 2012
University of Alabama Medical CenterResidency, Pediatrics, 2005 - 2008
Medical College of Georgia at Augusta UniversityClass of 2005

Certifications & Licensure

GA State Medical License 2010 - 2025
AL State Medical License 2007 - 2009
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Completed
Phase 2
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Start of enrollment: 2015 Dec 01
Withdrawn
Phase 1

Publications & Presentations

PubMed

43 citations
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Andrew E. Place, Yana Pikman, Kristen E. Stevenson, Marian H. Harris, Melinda Pauly
Pediatric Blood & Cancer. 2018-07-01
8 citations
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.
Daniel V. Runco, Cassandra D. Josephson, Sunil S. Raikar, Kelly C. Goldsmith, Glen Lew
Transfusion. 2018-05-01
7 citations
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium
Yana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen E. Stevenson, Traci M. Blonquist
Cancer Discovery. 2021-06-01

Abstracts/Posters

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Melinda Pauly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Children’s Healthcare of Atlanta Opens First Clinical Trial for New Therapy Targeting LeukemiaApril 12th, 2023